Document is current
Any future updates will be listed below
-
Authors
Imtiaz, Sara
Zafar, Rubia
Tahir, Amber
Abdeali, Mariam
Ahmed, Farrukh
Mansoor, Amna
Khan, Asima
Fawwad, Asher
Basit, Abdul
Walker, Simon
Afaq, Saima
Rehman, Khalid
Khan, Zohaib
Kanaan, Mona
Jennings, Hannah Maria
Shahab, Abdul Rahman
Siddiqi, Kamran
Haq, Zia Ul
-
Funding
Funding for this research was provided by:
National Institute of Health and Care Research (NIHR203248)
- License Information
-
More Information
Article History
Received: 2 November 2024
Accepted: 23 December 2025
First Online: 3 February 2026
Declarations
:
: The EMPOWER-D protocol has been granted ethical approval by the National Bioethics Committee of Pakistan (NBC-R-1070). Additionally, ethics approvals from the Ethics Review Committee of The Aga Khan University (2024-9340-28927), Khyber Medical University (KMU/IPHSS/Ethics/2023/EO/0136) and Baqai Institute of Diabetes and Endocrinology (BIDE/IRB/ABDULBASIT/05/15/24/025) have also been obtained.The study will adhere to the MRC Good Clinical Practice guidelines [ ] and the National Health Service (NHS) Research Governance Framework [ ]. The trial will uphold participants’ human rights and dignity as outlined in the 1996 Declaration of Helsinki [ ]. Informed written consent will be taken from all participants included in the assessments and the intervention after informing them about the study's purpose, procedures, potential risks, and benefits. Participants will not receive financial incentives for their involvement.
: Not applicable.
: The authors declare that they have no competing interests.
